respect
diabet
respect
cardiovascular
diseas
respect
present
fever
respect
short
breath
respect
compar
nonspecif
antivir
therapi
prevent
clinic
progress
sever
pneumonia
although
fewer
hypertens
patient
angiotensinconvert
enzym
inhibitor
angiotensinreceptor
blocker
aceiarb
therapi
develop
sever
pneumonia
contrast
nonaceiarb
hypertens
without
receiv
aceiarb
therapi
independ
risk
factor
odd
ratio
ci
develop
sever
pneumonia
irrespect
age
besid
none
patient
treat
chloroquin
develop
sever
pneumonia
though
without
signific
differ
ci
propens
score
match
conclus
relev
hypertens
patient
acei
arb
may
protect
sever
pneumonia
henc
therapi
ceas
unless
strong
indic
epidemiolog
evid
though
none
current
antivir
immunoregul
therapi
show
benefit
prevent
progress
chloroquin
deserv
investig
world
wit
rapid
escal
coronaviru
diseas
caus
sever
acut
respiratori
syndrom
coronaviru
becom
global
pandem
mani
patient
may
asymptomat
experi
mild
symptom
report
far
identifi
elderli
patient
chronic
comorbid
hypertens
diabet
cardiovascular
diseas
higher
risk
progress
sever
pneumonia
character
acut
respiratori
distress
syndrom
ard
andor
multiorgan
failur
sever
patient
requir
intens
medic
resourc
util
wors
prognosi
case
fatal
rate
time
higher
nonsever
patient
implement
effect
prevent
measur
essenti
clearli
exist
urgent
need
intervent
modul
diseas
progress
face
increas
number
infect
individu
overwhelm
capac
hospit
system
countri
specif
therapi
current
progress
investig
therapi
includ
develop
trial
coronaviru
vaccin
interrog
sever
orphan
drug
random
control
trial
rct
includ
remdesivir
garner
interest
ongo
adapt
rct
nucleotid
analogu
includ
ritonavir
favipiravir
galidesvir
recent
publish
openlabel
rct
show
benefit
proteas
inhibitor
lopinavirritonavir
reduc
clinic
sever
mortal
associ
despit
vitro
evid
activ
drug
interest
includ
antivir
therapi
pegyl
interferonalpha
arbidol
immunomodul
hydroxychloroquin
also
investig
result
eagerli
monitor
ccbyncnd
intern
licens
made
avail
authorfund
grant
medrxiv
licens
display
preprint
perpetu
peerreview
copyright
holder
preprint
inhibit
spike
glycoprotein
sprotein
may
also
viabl
target
recent
garner
increas
interest
particularli
potenti
interact
angiotensinogen
convert
enzym
propos
bind
sprotein
function
receptor
result
proteolyt
cleavag
type
ii
transmembran
serin
proteas
consider
interest
debat
regard
risk
sever
pneumonia
patient
angiotensinogen
convert
enzym
inhibitor
acei
angiotensin
receptor
blocker
arb
therapi
presum
modul
express
role
acei
arb
infect
remain
controversi
data
adjust
confound
factor
age
comorbid
definit
show
acei
arb
independ
associ
wors
outcom
cours
show
causal
either
henc
variou
independ
medic
societi
put
posit
statement
recogn
potenti
risk
given
current
qualiti
evid
recommend
inappropri
cessat
switch
aceiarb
therapi
hypertens
given
proven
benefit
therefor
object
studi
investig
role
sever
adjuv
treatment
prevent
sever
pneumonia
patient
seven
citi
hunan
provinc
china
institut
review
board
third
xiangya
hospit
central
south
univers
approv
studi
waiv
inform
consent
retrospect
natur
studi
consecut
adult
patient
confirm
treat
third
xiangya
hospit
central
ccbyncnd
intern
licens
made
avail
authorfund
grant
medrxiv
licens
display
preprint
perpetu
peerreview
copyright
holder
preprint
extract
demograph
exposur
histori
comorbid
clinic
symptom
laboratori
data
admiss
electron
medic
record
medic
histori
among
individu
hypertens
record
includ
aceiarb
calciumantagonist
blocker
diuret
agent
laboratori
test
perform
accord
clinic
care
need
patient
hospit
includ
complet
blood
count
assess
liver
renal
function
coagul
test
measur
electrolyt
creatin
kinas
lactat
dehydrogenas
procalcitonin
creactiv
protein
use
antivir
therapi
arbidol
lopinavirritonavir
interferon
chloroquin
obtain
medic
administr
record
sever
degre
time
admiss
defin
follow
mild
type
fever
respiratori
tract
symptom
without
radiolog
pneumonia
moder
type
fever
respiratori
tract
symptom
radiolog
evid
pneumonia
sever
type
ccbyncnd
intern
licens
made
avail
authorfund
grant
medrxiv
licens
display
preprint
perpetu
peerreview
copyright
holder
preprint
one
follow
respiratori
distress
respiratori
rate
beatsmin
b
hypoxia
oxygen
satur
rest
state
c
hypoxemia
arteri
blood
oxygen
partial
pressureoxygen
concentr
critic
type
one
follow
respiratori
failur
requir
mechan
ventil
b
shock
c
intens
care
unit
icu
admiss
requir
combin
organ
failur
studi
sever
pneumonia
broadli
includ
sever
critic
type
ct
imag
acquir
admiss
interv
day
review
independ
two
experienc
radiologist
typic
ct
find
defin
peripher
distribut
multifoc
groundglass
opac
ggo
patchi
consolid
posterior
part
lower
lobe
involv
predilect
five
lung
lobe
review
ggo
consolid
lesion
extent
within
lung
lobe
semiquantit
evalu
score
base
degre
involv
score
none
involv
score
involv
score
involv
score
involv
score
involv
score
involv
total
score
calcul
sum
score
five
lobe
provid
lung
ct
score
rang
mean
valu
lung
ct
score
evalu
two
radiologist
use
analysi
primari
outcom
analysi
progress
sever
pneumonia
continu
variabl
present
median
interquartil
rang
iqr
categor
variabl
present
frequenc
percentag
differ
group
analyz
use
student
ttest
mannwhitney
u
test
quantit
variabl
accord
normal
distribut
chisquar
test
fisher
exact
test
categor
variabl
meanwhil
differ
ccbyncnd
intern
licens
made
avail
authorfund
grant
medrxiv
licens
display
preprint
perpetu
peerreview
copyright
holder
preprint
distribut
also
report
use
differ
confid
interv
ci
univari
multivari
logist
regress
backward
stepwis
select
base
likelihood
ratio
use
identifi
risk
factor
develop
sever
pneumonia
correspond
odd
ratio
or
ci
determin
also
employ
propens
score
match
psm
ratio
minim
select
bia
adjust
imbal
patient
without
chloroquin
therapi
onetoon
nearestneighbour
match
algorithm
optim
callip
without
replac
use
gener
pair
patient
analys
regard
differ
factor
base
nonmiss
data
miss
data
imput
statist
analys
perform
use
spss
statist
softwar
version
ibm
spss
inc
chicago
il
usa
twosid
p
valu
less
consid
statist
signific
studi
popul
includ
adult
patient
confirm
nine
hospit
seven
citi
figur
clinic
characterist
admiss
present
tabl
ccbyncnd
intern
licens
made
avail
authorfund
grant
medrxiv
licens
display
preprint
perpetu
peerreview
copyright
holder
preprint
median
lung
ct
score
iqr
rang
total
patient
identifi
sever
pneumonia
summar
tabl
patient
older
like
preexist
comorbid
includ
hypertens
diabet
cardiovascular
diseas
copd
chronic
renal
diseas
compar
nonsever
patient
clinic
symptom
ill
onset
also
differ
sever
patient
like
present
fever
short
breath
ci
p
howev
lymphocyt
count
differ
ci
p
significantli
lower
patient
sever
pneumonia
thirti
patient
classifi
sever
pneumonia
admiss
exclud
leav
patient
nonsever
admiss
analysi
amongst
group
patient
develop
sever
pneumonia
hospit
n
patient
receiv
singl
combin
antivir
therapi
admiss
adjust
age
gender
smoke
histori
hypertens
diabet
cardiovascular
diseas
copd
lung
ct
score
none
investig
antivir
therapi
p
associ
reduc
risk
progress
sever
diseas
shown
tabl
ccbyncnd
intern
licens
made
avail
authorfund
grant
medrxiv
licens
display
preprint
perpetu
peerreview
copyright
holder
preprint
eightytwo
individu
record
hypertens
patient
aceiarb
therapi
includ
case
receiv
arb
monotherapi
case
receiv
combin
arb
calciumantagonist
case
receiv
aeci
monotherapi
patient
nonaceiarb
antihypertens
therapi
includ
case
receiv
calciumantagonist
monotherapi
case
receiv
blocker
monotherapi
case
receiv
diuret
monotherapi
case
receiv
combin
calciumantagonist
blocker
maintain
usual
antihypertens
regimen
hospit
remain
case
antihypertens
medic
limit
unavail
data
receiv
amlodipin
nitrendipin
control
blood
pressur
necessari
summar
tabl
ccbyncnd
intern
licens
made
avail
authorfund
grant
medrxiv
licens
display
preprint
perpetu
peerreview
copyright
holder
preprint
tabl
none
patient
treat
chloroquin
develop
sever
pneumonia
though
without
signific
differ
ci
p
addit
signific
differ
report
advers
event
grade
advers
event
two
group
p
respect
studi
describ
use
sever
adjuv
treatment
prevent
sever
pneumonia
develop
patient
hypertens
patient
receiv
aceiarb
therapi
lower
risk
develop
sever
pneumonia
compar
nonaceiarb
antihypertens
therapi
suggest
aceiarb
therapi
may
protect
sever
pulmonari
injuri
hypertens
patient
howev
result
interpret
caution
owe
potenti
bia
residu
confound
observ
studi
consist
earlier
report
clinic
experi
around
world
cohort
confirm
ccbyncnd
intern
licens
made
avail
authorfund
grant
medrxiv
licens
display
preprint
perpetu
peerreview
copyright
holder
preprint
older
age
hypertens
without
aceiarb
therapi
independ
associ
develop
sever
pneumonia
associ
age
sever
pneumonia
may
attribut
accumul
medic
comorbid
age
declin
immun
function
time
given
close
collinear
age
hypertens
studi
adjust
age
multivari
regress
analysi
reveal
hypertens
remain
independ
risk
factor
diseas
progress
irrespect
age
patient
without
receiv
aceiarb
therapi
studi
examin
controversi
topic
aceiarb
therapi
hypertens
patient
found
hypertens
patient
aceiarb
therapi
less
like
develop
sever
pneumonia
although
acknowledg
analysi
conduct
limit
sampl
size
patient
acei
arb
therapi
dynam
profil
laboratori
radiolog
find
show
patient
aceiarb
therapi
lactos
dehydrogenas
ct
lung
score
lower
nonaceiarb
therapi
day
admiss
togeth
find
suggest
acei
arb
therapi
may
protect
hypertens
patient
patient
hypertens
may
endur
wors
outcom
due
decreas
level
import
compon
reninangiotensinaldosteron
system
raa
highli
express
lung
myocardium
convert
angiotensin
ii
aii
angiotensin
downregul
ace
directli
caus
vasodilat
downregul
level
also
shown
hypertens
anim
model
although
limit
success
translat
confirm
human
studi
none
less
may
exacerb
reduct
avail
follow
coronaviru
infect
sarscov
ccbyncnd
intern
licens
made
avail
authorfund
grant
medrxiv
licens
display
preprint
perpetu
peerreview
copyright
holder
preprint
gain
entri
host
cell
bind
sprotein
membranebound
aminopeptidas
cleav
serin
proteas
allow
membran
fusion
invas
follow
infect
reduct
pulmonari
either
intern
viral
entri
andor
downregul
enzym
process
henc
may
exacerb
lower
baselin
function
hypertens
patient
lead
accumul
aii
reduc
angiotensin
subsequ
wors
immunerel
cytolysi
lung
injuri
valid
linear
associ
elev
plasma
aii
level
viral
load
lung
injuri
patient
use
acei
arb
like
promot
feedback
upregul
express
hypertens
although
anim
human
studi
also
found
either
effect
downregul
level
set
diabet
hypertens
cardiovascular
diseas
without
acearb
therapi
nonetheless
may
explain
find
aceiarb
therapi
protect
infect
evid
would
support
come
earlier
studi
aceistatin
protect
sever
pneumonia
recombin
protect
mice
lung
injuri
follow
sarscov
infect
raa
blockad
reduc
acut
lung
injuri
rat
inject
sarscov
sprotein
current
still
specif
treatment
except
support
care
cohort
nonsever
patient
receiv
nonspeci
antivir
therapi
admiss
combin
protocol
medic
dose
vari
differ
hospit
howev
result
support
singl
combin
antivir
treatment
limit
progress
addit
none
patient
treat
chloroquin
develop
sever
pneumonia
though
without
statist
signific
unfortun
limit
degre
heterogen
ccbyncnd
intern
licens
made
avail
authorfund
grant
medrxiv
licens
display
preprint
perpetu
peerreview
copyright
holder
preprint
cohort
rel
small
size
chloroquin
known
block
viru
infect
increas
endosom
ph
requir
viruscel
fusion
well
interf
glycosyl
cellular
receptor
coronaviru
confirm
inhibit
vitro
recent
open
label
non
random
clinic
trial
report
hydroxychloroquin
combin
azithromycin
significantli
associ
viral
load
reductiondisappear
patient
even
rct
assess
therapeut
effect
chloroquin
need
conduct
sever
limit
studi
first
studi
conduct
retrospect
data
analysi
second
case
incomplet
laboratori
test
result
given
variat
clinic
manag
among
differ
hospit
data
gener
clinic
driven
systemat
third
patient
recov
discharg
time
data
cutoff
patient
die
admiss
impact
adjuv
treatment
clinic
outcom
analyz
forth
limit
hypertens
patient
receiv
acei
arb
therapi
analyz
effect
aeci
arb
respect
larger
cohort
studi
patient
hypertens
citi
china
countri
would
help
valid
potenti
protect
effect
aeciarb
therapi
fastevolv
global
pandem
high
mortal
sever
pneumonia
ard
multiorgan
failur
highest
risk
elderli
patient
underli
hypertens
current
adjuv
antivir
immunoregul
therapi
yet
proven
ccbyncnd
intern
licens
made
avail
authorfund
grant
medrxiv
licens
display
preprint
perpetu
peerreview
copyright
holder
preprint
http
doi
medrxiv
preprint
benefit
clinic
set
importantli
result
show
potenti
protect
effect
acei
arb
therapi
limit
progress
sever
lung
diseas
hypertens
patient
ccbyncnd
intern
licens
made
avail
authorfund
grant
medrxiv
licens
display
preprint
perpetu
peerreview
copyright
holder
preprint
figur
studi
design
flow
chart
includ
patient
ccbyncnd
intern
licens
made
avail
authorfund
grant
medrxiv
licens
display
preprint
perpetu
peerreview
copyright
holder
preprint
ccbyncnd
intern
licens
made
avail
authorfund
grant
medrxiv
licens
display
preprint
perpetu
peerreview
copyright
holder
preprint
http
doi
medrxiv
preprint
abbrevi
acei
angiotensinconvert
enzym
inhibitor
arb
angiotensinreceptor
blocker
ci
confid
interv
copd
chronic
obstruct
pulmonari
diseas
ct
comput
tomographi
ccbyncnd
intern
licens
made
avail
authorfund
grant
medrxiv
licens
display
preprint
perpetu
peerreview
copyright
holder
preprint
http
doi
medrxiv
preprint
ccbyncnd
intern
licens
made
avail
authorfund
grant
medrxiv
licens
display
preprint
perpetu
peerreview
copyright
holder
preprint
